triazolam has been researched along with Hemisensory Neglect in 1 studies
Triazolam: A short-acting benzodiazepine used in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most other countries.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We report two cases of severe withdrawal symptoms after abrupt discontinuation of a long-term normal-dose benzodiazepines (BZD) administration." | 1.27 | [Two cases of psychotic state following normal-dose benzodiazepine withdrawal]. ( Tani, Y; Terao, T, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Terao, T | 1 |
| Tani, Y | 1 |
1 other study available for triazolam and Hemisensory Neglect
| Article | Year |
|---|---|
[Two cases of psychotic state following normal-dose benzodiazepine withdrawal].
Topics: Anti-Anxiety Agents; Cognition Disorders; Female; Humans; Male; Middle Aged; Nitrazepam; Perceptual | 1988 |